Study of Methylene Tetrahydrofolate Reductase enzyme Activity in Diffuse Large B-cell Non-Hodgkin's Lymphoma Patients Ali Abdulhur Arnos* PhD, Waseem F Al Tameemi** MD CABM, Noor Mustafa Ali* PhD
Background: Diffuse large B-cell lymphoma is a heterogeneous disease with recognized variability in clinical outcome, genetic features, and cells of origin. It is the most common lymphoid malignancy in adults, comprising almost 40% of all lymphoid tumors.
Objective: To study of methylene tetrahydrofolate reductase in diffuse large B cell non-Hodgkin lymphoma patients.
Methods: This case control study was conducted during the period from April 2015 to December 2015 on 55 patients 19 patients before treatment and 36 patients after treatment. The patients were diagnosed as having diffuse large B cell non-Hodgkin lymphoma. Those patients were attending the Medical City Hospital in Baghdad and Immammain Kadhimain Medical City Hospital, in addition to another 30 apparently healthy individuals as control group. Both patient and control groups were examined and reviewed clinically and assessed by basic laboratory investigation. High pressure liquid chromatography technique was used for the estimation of methylene tetrahydrofolate reductase level (μg/dl) in diffuse large B cell non-Hodgkin lymphoma patients and controls.
Results: Methylene tetrahydrofolate reductase enzyme level showed significant difference between patients and control (P value ≤ 0.05). It was significantly lower in advanced compared to limited stage large B-cell non-Hodgkin’s lymphoma; moreover methylene tetrahydrofolate reductase enzyme was significantly higher for both advanced and limited stage large B-cell non-Hodgkin's lymphoma patient after treatment compared to their level before treatment (P = 0.001) and (P value = 0.009), respectively.
Conclusion: Methylene tetrahydrofolate reductase enzyme level was inversely related to disease progression. Throughout course of treatment, the methylene tetrahydrofolate reductase activity was increased as the disease being under effect of chemotherapy. Therefore, folate supplementation may be useful to avoid metabolic disturbance and consequence of hyperhomocysteinemia and decrease of methionine.
Copyright (c) 2019 Iraqi Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share — copy and redistribute the material in any medium or format
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.